<DOC>
	<DOCNO>NCT01054430</DOCNO>
	<brief_summary>The objective study ass single dose pharmacokinetics avanafil subject hepatic impairment healthy control subject .</brief_summary>
	<brief_title>To Assess Safety Avanafil Healthy Hepatically Impaired Male Subjects .</brief_title>
	<detailed_description />
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>Male subject must 2175 year age ; inclusive . Healthy control subject ( Cohort 1 ) must medically healthy clinically insignificant screen result hepatically impaired subject ( Cohorts 2 3 ) must mild moderate hepatic impairment base ChildPugh Classification . Main exclusion criterion healthy control subject ( Cohort 1 ) include history clinical evidence clinically relevant cardiovascular ( include thromboembolic disorder ) , hepatic , renal , hematologic , endocrine , pulmonary , gastrointestinal , psychiatric neurological impairment ; clinically significant laboratory abnormality judge investigatorInvestigator ; systolic blood pressure &lt; 90 &gt; 160 mmHg ; diastolic blood pressure &lt; 50 &gt; 90 mmHg ; allergy previous adverse event PDE5 inhibitor ; use prescription overthecounter drug know interfere metabolism cytochrome P450 3A4 enzyme within 30 day screen ; use investigational drug within 30 day screen ; use prescription overthecounter drug herbal remedy within 14 day screen ; history alcohol drug abuse within 18 month , history smoking within 6 month ; positive breath alcohol test ; positive serology HIV , HCV , HBsAg ; blood donation significant blood loss within 56 day dose ; plasma donation within 7 day dose . Main exclusion criterion hepatically impaired subject ( Cohorts 2 3 ) include significant concurrent medical condition history significant medical condition hepatic impairment may affect interpretation data otherwise contraindicate participation study ; acute exacerbation unstable hepatic disease , indicate worsen clinical and/or laboratory sign hepatic impairment , within 2 week precede study drug administration ; history esophageal variceal bleeding within past 6 month ; history bleed nonbleeding gastric varix ; history spontaneous bacterial peritonitis within past 3 month ; history portosystemic surgical shunt ; autoimmune liver disease ; history organ transplant ; Wilson 's disease ; diagnosis cholestatic liver disease ( e.g. , primary biliary cirrhosis primary sclerosing cholangitis ) ; history recent symptomatic cryoglobulinemia ; alcoholic hepatitis , determine clinically histology ; initiation new prescription counter medication within 14 day study drug administration hemoglobin &lt; 9.0 g/dL , positive AFP .</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Avanafil</keyword>
	<keyword>Hepatic</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Impairment</keyword>
</DOC>